Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) just unveiled an update.
Zhaoke Ophthalmology Limited has announced the renewal of a lease agreement for premises in Guangzhou, China, with Lee’s Pharmaceutical Holdings Limited. The renewed lease, effective from April 1, 2025, to February 29, 2028, involves a monthly rental fee of approximately RMB666,011.72 for office, manufacturing, and warehouse use. This transaction is considered a connected transaction under Hong Kong’s Listing Rules and will be treated as an acquisition of a capital asset, impacting the company’s balance sheet under IFRS 16.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on ophthalmology pharmaceuticals. It operates through its subsidiaries, including Zhaoke Guangzhou, and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 63.33%
Average Trading Volume: 2,512,736
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.06B
Learn more about 6622 stock on TipRanks’ Stock Analysis page.